# Ribociclib

## Kisqali 200mg

| 藥物代碼 | OKIS |
| :--- | :--- |
| 適應症 | Treatment of hormone receptor \(HR\)-positive, human epidermal growth factor receptor 2 \(HER2\)-negative advanced or metastatic breast cancer \(in combination with an aromatase inhibitor\) in postmenopausal women as initial endocrine-based therapy. |
| 副作用 | &gt;10%:Cardiovascular: Peripheral edema \(12%\)Central nervous system: Fatigue \(37%\), headache \(22%\), insomnia \(12%\)Dermatologic: Alopecia \(33%\), skin rash \(17%\), pruritus \(14%\)Endocrine & metabolic: Decreased serum potassium \(11%\)Gastrointestinal: Nausea \(52%\), diarrhea \(35%\), vomiting \(29%\), constipation \(25%\), decreased appetite \(19%\), stomatitis \(12%\), abdominal pain \(11%\)Genitourinary: Urinary tract infection \(11%\)Hematologic & oncologic: Neutropenia \(75%; grade 3: 50%; grade 4: 10%\), leukopenia \(33%; grade 3: 20%; grade 4: 1%\), decreased platelet count \(29%; grade 3: 1%\), anemia \(18%; grade 4: &lt;1%\), abnormal phosphorus levels \(decreased; 13%; grade 3: 5%; grade 4: 1%\), lymphocytopenia \(11%; grade 3: 6%; grade 4: 1%\)Hepatic: Increased serum ALT \(&lt;46%\), increased serum AST \(&lt;44%\), increased serum bilirubin \(18%\)Neuromuscular & skeletal: Back pain \(20%\)Renal: Increased serum creatinine \(20%\)Respiratory: Dyspnea \(12%\)Miscellaneous: Fever \(13%\) |
| 禁忌 | Known hypersensitivity to Ribociclib succinate. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Breast cancer, advanced or metastatic: Females \(HR-positive, HER-2 negative\): Oral: 600 mg once daily for 21 days, followed by a 7-day rest period to complete a 28-day treatment cycle \(in combination with continuous letrozole, continue until disease progression or unacceptable toxicity. |
| 肝功能異常 | 需 調 整 劑 量  Moderate or severe impairment \(Child-Pugh class B or C\): Reduce initial dose to 400 mg/day. |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 不可使用 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | PO |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## Kisqali 200mg 63\#/盒\(sample\)

| 藥物代碼 | OKIS0 |
| :--- | :--- |
| 適應症 | NA |
| 副作用 | NA |
| 禁忌 | NA |
| 藥物保存方式 | N/A |
| 用法用量 | N/A |
| 肝功能異常 | 無需調整劑量  需調整劑量 |
| 腎功能異常 | 無需調整劑量  需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | N/A |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | PO |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

